A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) — PALBONET

Pancreatic Neuroendocrine Cancer Clinical Trial

Official title:
A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Status Completed

Clinical Trial Summary

A phase II trial to assess the activity and safety of PD0332991 in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1)

Clinical Trial Description

The purpose of this study is to evaluate the activity and safety of PD0332991 in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02806648
Study type	Interventional
Source	Grupo Espanol de Tumores Neuroendocrinos
Contact
Status	Completed
Phase	Phase 2
Start date	May 2015
Completion date	January 2018

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01603004` - Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors